Key facts
- Notable investors include Tech Incubator Program for Startup, BiiG WAVE, Innocube, WOW Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for AbFinder Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for AbFinder Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AbFinder Therapeutics
Developer of biopharmaceutical discovery platforms intended to focus on replacing peptide and antibody engineering technologies. The company operates an integrated antibody discovery and engineering platform, designed to streamline and optimize the creation of next-generation biologic drugs, and collaborates with biopharmaceutical and biotechnology partners through open innovation models, enabling medical professionals to accelerate therapeutic pipeline development and enhance the performance and differentiation of antibody-based therapies.
- Sector
- Healthcare
- HQ
- Anyang, South Korea
- Founded
- 2024
- Employees
- 5
- Website
- abfindertrx.com/
- Ownership
- Privately Held (backing)
AbFinder Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AbFinder Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AbFinder Therapeutics in its N-PORT filings yet. We sweep new filings monthly.